DPP-4抑制剂及其在2型糖尿病管理的潜在作用。

文章的细节

引用

复制到剪贴板

巴奈特一

DPP-4抑制剂及其在2型糖尿病管理的潜在作用。

Int中国Pract。2006年11月,60 (11):1454 - 70。

PubMed ID

17073841 (在PubMed

]

文摘

4 (DPP-4) dipeptidyl肽酶抑制剂增强身体自身的控制血糖的能力通过增加体内活跃的肠促胰岛素的激素水平。他们的作用机制是不同于任何现有类的口服降糖药物。他们控制血糖升高通过触发胰腺胰岛素分泌,抑制胰腺胰高血糖素分泌,和肝脏信号减少葡萄糖生产。主要DPP-4抑制剂临床显示显著的降低糖化血红蛋白治疗1年,提供许多潜在优势现有糖尿病疗法包括低血糖的风险很低,不影响体重,和潜力,基于动物和体外研究中,对胰岛细胞的再生和分化。他们有效的单一疗法并结合常用抗糖尿病的药物,适用于每天换一次口服给药。因此,许多DPP-4抑制剂如vildagliptin (Galvus;laf - 237), sitagliptin (Januvia;mk - 0431)和saxagliptin (bms - 477118)已经先进到后期人体临床试验。必威国际app搜索策略和选择标准本文是建立在系统的MEDLINE搜索出版物上的主题关键词:DPP-4抑制剂;vildagliptin (laf - 237); sitagliptin (MK-0431); saxagliptin (BMS-477118); and type 2 diabetes; up to August 2006. Meeting abstracts were also searched, as much of the data currently only exists in abstract form. Take home message for clinician The DPP-4 inhibitors appear to have great potential for the treatment of type 2 diabetes, but time will tell if this will be realized. While they do not lower glucose to a greater extent than existing therapies, they offer many potential advantages, including the ability to achieve sustainable reductions in HbA1c with a well-tolerated agent that has a low risk of hypoglycaemia and no weight gain, and which can be administered as a once-daily oral dose.

DrugBank数据引用了这篇文章

药物

Saxagliptin